Zhao R, et al. - Researchers tested riociguat as a management option for patients with pulmonary arterial hypertension by analyzing randomized controlled trials (RCTs) assessing the effect of riociguat treatment on pulmonary arterial hypertension. Using the random effects model, they carried out a meta-analysis with seven RCTs. Findings demonstrated that after riociguat treatment in patients with pulmonary arterial hypertension, a significant increase in the six-minute walking distance, EQ-5D score, and cardiac index, as well as a decrease in Living With Pulmonary Hypertension score and pulmonary vascular resistance was evident.